Navigation Links
Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
Date:5/19/2009

By 2018, Gilead's Quad Will Become the Highest-Selling Antiretroviral in the World's Major Markets, According to a New Report from Decision Resources

WALTHAM, Mass., May 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of antiretroviral agents will drive substantial six percent annual growth in the HIV drug market through 2013 but significant generic erosion of key therapies thereafter will slow annual growth to less than two percent from 2013 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Human Immunodeficiency Virus finds that continued increase in the uptake of Bristol-Myers Squibb/Gilead's Atripla will drive the agent to garner the highest sales of any antiretroviral in 2013. However, from 2013 to 2018, Gilead's Quad will make significant inroads in the HIV market and by 2018 will become the highest-selling antiretroviral drug in the world's major markets, according to the report. Quad will combine favorable safety and efficacy with the dosing convenience of a single daily pill regimen, making it an ideal product for treatment-naive patients.

"The largest commercial opportunities in the HIV market lie in the development of therapies with enhanced convenience, such as co-formulations that minimize the number of pills and frequency of dosing, especially safe and effective therapies that target treatment-naive patients -- the most lucrative segment of the market," said Decision Resources Analyst Jose Avalos, Ph.D. "In addition, agents with reduced long-term toxicities can differentiate themselves in this crowded market."

The report also finds that two novel classes of antiretroviral agents -- the integrase inhibitors and CCR5 antagonists -- have been received with different levels of enthusiasm among interviewed experts and prescribers. Merck's Isentress, the first integrase inhibitor on the market, has been received with great enthusiasm by physicians and patients because of its efficacy, safety, and simple dosing. In contrast, Pfizer's Selzentry, the first-in-class CCR5 antagonist, has experienced significant obstacles that include its limited patient eligibility and the lengthy tropism test required for its prescription. The landscape for CCR5 antagonists is expected to improve, however, once better tropism tests and improved protocols are established.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                          Decision Resources, Inc.
    Christopher Comfort                         Elizabeth Marshall
    781-296-2597                                781-296-2563
    ccomfort@dresources.com                     emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Psychemedics Corporation Announces Sales & Marketing Agreement With Bupa in UK
2. GeckoSystems Reveals Eldercare Capable Personal Robot Sales Forecasts
3. Herbal Supplement Sales Increase in US in 2008
4. U.S. Mobile Robot Co. Reveals Pacific Rim Sales Forecasts
5. Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
6. OrthoSynetics Selects Landslides Sales P3 System as its Corporate Sales System
7. RBC Life Sciences North American Nutritional Supplements and Medical Products Sales Increased, Year Over Year, During the First Quarter of 2009
8. Milestone Scientific Reports Strong Sales Growth in First Quarter 2009 Results
9. Woodward Labs Reports Sales Spike for HandClens(R) Alcohol-Free Hand Sanitizer During Swine Flu Epidemic
10. Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008
11. Archi-Tech InView Now Supports Managed Care Data, Offering an Interactive Dashboard for On-Demand Sales Planning and Reporting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... "FCPX editors can now reveal their media with growing colorful ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings the ... can now reveal the media of their split screens with growing colorful panels. , ...
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Story Highlights: , ... health care industry is causing providers to review operating ... offers a suite of solutions for health care providers ... optimization: labor resource analysis, revenue cycle optimization and physician ... and better economics ...
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
Breaking Medicine Technology: